Midway Immunology and Research Center | ClinicalTrials HQ

11 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance	HIV-1-infection	Active, not recruiting	Phase 2 / Phase 3	2026-10-01		NCT04150068
Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1	HIV-1 Infection	Active, not recruiting	Phase 2 / Phase 3	2026-09-24		NCT02881320
Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 Treatment	HIV-1-infection	Recruiting	Phase 2 / Phase 3	2026-09-09		NCT07708727
A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1	HIV-1-infection	Recruiting	Phase 2	2026-09-04		NCT07645287
Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP)	HIV Pre-exposure Prophylaxis	Active, not recruiting	Phase 3	2026-08-28		NCT07047716
Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy	Blood-Borne Infections, Genital Diseases, HIV infectious disease, Infections, RNA Virus Infections, Urogenital Diseases, immune system disorder, inborn error of immunity, infectious disease, lentivirus infection, sexually transmitted disease, uterine carcinosarcoma, viral infectious disease, viral sexually transmitted disease	Recruiting	Phase 3	2026-08-14		NCT07682961
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy	HIV-1-infection	Active, not recruiting	Phase 3	2026-06-15		NCT06333808
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1	HIV-1-Infection	Active, not recruiting	Phase 3	2026-05-29		NCT06630299
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1	HIV-1-infection	Active, not recruiting	Phase 3	2026-04-30		NCT06630286
A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection	HIV-1 Infection	Active, not recruiting	Phase 2	2026-04-27		NCT05729568
Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV	HIV-1 Infection	Active, not recruiting	Phase 2	2026-02-04		NCT05052996